Hideyuki Igawa

Hideyuki Igawa

Auto-generated profile, based on publicly available information

Hideyuki Igawa

Schrödinger Inc

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ALAbba Leffler
Abba Leffler
EHEvelyne M. Houang
Evelyne M. Houang
FGFelicia Gray
Felicia Gray
APAndrew T. Placzek
Andrew T. Placzek
ARAnatoly M. Ruvinsky
Anatoly M. Ruvinsky
ALAdam M. Levinson
Adam M. Levinson

13 December 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLH. Rachel Lagiakos
H. Rachel Lagiakos
YZYefen Zou
Yefen Zou
HIHideyuki Igawa
Hideyuki Igawa
ETEric Therrien
Eric Therrien
MLMorgan Lawrenz
Morgan Lawrenz
ZNZhe Nie
Zhe Nie

12 December 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HIHideyuki Igawa
Hideyuki Igawa
ZKZef A. Konst
Zef A. Konst
ETEric Therrien
Eric Therrien
MSMee Shelley
Mee Shelley
HKHeidi Koldsø
Heidi Koldsø
AGAleksey I. Gerasyuto
Aleksey I. Gerasyuto

21 June 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
HIHideyuki Igawa
Hideyuki Igawa
ZKZef A. Konst
Zef A. Konst
ETEric Therrien
Eric Therrien
MSMee Shelley
Mee Shelley
HKHeidi Koldsø
Heidi Koldsø
AGAleksey I. Gerasyuto
Aleksey I. Gerasyuto
Despite the success of first, second and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in treatment of non-small cell lung cancer (NSCLC) with classical EGFR mutations (L858R or Exon 19 deletions), disease progression often occurs due to the acquisition of additional mutations in the EGFR kinase domain that confer TKI resistance. Specifically, acquisition of both T790M and C797S resistance mutations results in an EGFR variant that is resistant to all approved EGFR TKIs. Herein, we report a physics-based computationally-driven lead identification approach which successfully identified structurally-unique imidazo[3.2-b]pyrazole derivatives as reversible inhibitors of EGFR classical mutations bearing both T790M and C797S. Importantly, they spare EGFR WT to avoid known EGFR WT-driven cutaneous toxicities. During profiling of imidazo[3.2-b]pyrazole derivatives, we elucidated the bioactivation mechanism causing CYP3A4/5 time-dependent inhibition (TDI) and found key modifications to suppress bioactivation and mitigate the TDI risk. Representative lead compound 31 inhibited EGFR L858R/T790M/C797S in biochemical assays with a Ki = 2.1 nM, and EGFR del19/T790M/C797S in a Ba/F3 cellular assay with a IC50 = 56.9 nM. Deuterated analog of 31 (38) demonstrated dose-dependent tumor growth inhibition in a Ba/F3 EGFR del19/T790M/C797S CDX model by 47% at 50 mg/kg BID and 92% at 100 mg/kg BID.

25 November 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
HLH. Rachel Lagiakos
H. Rachel Lagiakos
YZYefen Zou
Yefen Zou
HIHideyuki Igawa
Hideyuki Igawa
ETEric Therrien
Eric Therrien
MLMorgan Lawrenz
Morgan Lawrenz
ZNZhe Nie
Zhe Nie
Dual leucine zipper kinase (DLK), expressed primarily in neuronal cells, is a regulator of neuronal degeneration in response to cellular stress from chronic disease or neuronal injury. This makes it an attractive target for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis; and neuronal injury, such as chemotherapy induced peripheral neuropathy. Here we describe the discovery of a potent, selective, brain-penetrant DLK inhibitor, KAI-11101 (59). Throughout the program's progression, medicinal chemistry challenges such as potency, hERG inhibition, CNS penetration, CYP3A time-dependent inhibition, and kinase selectivity were overcome through the implementation of cutting-edge in silico tools. KAI-11101 displayed an excellent in vitro safety profile and showed neuroprotective properties in an ex vivo axon fragmentation assay as well as dose-dependent activity in a mouse PD model.

13 January 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
MLMorgan Lawrenz
Morgan Lawrenz
MSMats Svensson
Mats Svensson
MKMitsunori Kato
Mitsunori Kato
KDKaren Dingley
Karen Dingley
JEJackson Chief Elk
Jackson Chief Elk
ETEric Therrien
Eric Therrien
The blood-brain barrier (BBB) plays a critical role in preventing harmful endogenous and exogenous substances from penetrating the brain. Optimal brain penetration of small molecule CNS drugs is characterized by a high unbound brain/plasma ratio (Kp,uu). While various medicinal chemistry strategies and in silico models have been reported to improve BBB penetration, none were developed to predict Kp,uu directly. We describe a physics-based computational approach, solvation free energy calculations (energy of solvation or E-sol), to predict Kp,uu. Prospective application of this method to internal CNS drug discovery programs highlighted the utility and accuracy of this new method, which showed a categorical accuracy of 79% and a R2 of 0.61 from a linear regression model.